constructed a radiomic model may aid in predicting the acquired drug‐resistant mutation T790M following targeted therapy for lung cancer, suggesting the potential application of radiogenomic models in optimizing EGFR‐targeted therapy decisions. This evidence concerns the gene EGFR and lung cancer.